Early diagnosis of ovarian and endometrial cancer using genomic testing

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to develop and validate a genomic test for the early diagnosis of ovarian and endometrial cancers by detecting somatic mutations in biofluid samples collected from the cervix and uterine cavity. Given the high mortality rates associated with late-stage diagnoses, the research focuses on utilizing advanced DNA-tagging technologies to identify cancer-associated mutations at an early stage. The goal is to create a highly sensitive and specific assay that can be automated for high-throughput testing, potentially transforming the current diagnostic approach for these cancers.

Why it matters

Who can join: the full rules

Case Inclusion:

* Subjects should have suspected or confirmed cancer of the upper genital tract.
* Participant will undergo surgery for tumour removal.

Control inclusion:

• Subjects should be scheduled to have a hysterectomy, bilateral salpingectomy, with or without bilateral oophorectomy, for presumed benign disease.

Where it's running

• Royal Victoria Hospital (Glen Site)
  Montreal, Quebec, Canada Recruiting

Study contacts

• Study coordinator: Dr. Lucy Gilbert, MD,MSc,FRCOG
• Email: lucy.gilbert@mcgill.ca
• Phone: (514) 934-1934

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Evaluating NKT3964 for Adults with Advanced Solid Tumors

  This study is testing a new drug called NKT3964 to see if it can safely help adults with advanced solid tumors, like ovarian or triple-negative breast cancer, after other treatments have failed.

  Recruiting at 17 sites Phase 1 NiKang Therapeutics, Inc. · Little Rock, Arkansas and 20 other locations · NCT06586957

• National registry for ovarian and endometrial cancer patients

  This study is setting up a national registry to track information about patients with advanced ovarian and endometrial cancer in Germany to see how they respond to different treatments over time.

  Recruiting iOMEDICO AG · Multiple Locations · NCT05129969

• CR-002 study in adults with advanced solid tumors

  This trial tests CR-002 as a single therapy to see if it is safe and tolerable in adults with locally advanced or metastatic solid tumors

  Recruiting at 3 sites Phase 1/2 Crescent Biopharma, Inc. · Austin, Texas and 2 other locations · NCT07909031

• Methylation markers in self-samples to help detect gynecological cancers

  This study tests whether self-collected urine and vaginal samples can reveal DNA methylation or other genetic markers that indicate endometrial, ovarian, vulvar, or vaginal cancers in women who are at risk or have postmenopausal bleeding.

  Recruiting Universiteit Antwerpen · Edegem, Antwerp · NCT07902375

• Radiotherapy for gynecologic cancer with up to 10 metastatic sites

  This registry follows adults with gynecologic cancer who have 1 to 10 active metastatic lesions and are treated with radiotherapy as part of routine care to see how such treatments work in real-world settings.

  Recruiting Affidea Nu-med Center of Oncological DIagnostics and Therapy · Zamość · NCT07883798

• Stellate ganglion block and dexmedetomidine for better sleep after gynecologic laparoscopy

  The study tests whether giving a preoperative stellate ganglion block plus intraoperative dexmedetomidine improves sleep after laparoscopic gynecologic surgery in women.

  Recruiting The Second People's Hospital of Huai'an · Huai'an, Jiangsu · NCT07860203

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.